{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:32:28Z","timestamp":1791415948346,"version":"4.3.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Emergent Biosolutions"},{"name":"Valneva Austria GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Zika virus (ZIKV) is an emerging public health threat, rendering development of a safe and effective vaccine against the virus a high priority to face this unmet medical need. Our vaccine candidate has been developed on the same platform used for the licensed vaccine IXIARO\u00ae, a vaccine against Japanese Encephalitis virus, another closely related member of the Flaviviridae family.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between 24 February 2018 and 16 November 2018, we conducted a randomized, observer-blinded, placebo controlled, single center phase 1 study to assess the safety and immunogenicity of an adjuvanted, inactivated, purified whole-virus Zika vaccine candidate in the USA. A total of 67 healthy flavivirus-na\u00efve adults aged 18\u201349\u00a0years were randomly assigned to one of five study arms to receive two immunizations of either high dose or low dose (6 antigen units or 3 antigen units) with both dose levels applied in two different immunization regimens or placebo as control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our vaccine candidate showed an excellent safety profile independent of dose and vaccination regimen with predominantly mild adverse events (AEs). No serious AE has been reported. The ZIKV vaccine induced neutralizing antibodies in all tested doses and regimens with seroconversion rates up to 85.7% (high dose), which remained up to 40% (high dose) at 6\u00a0months follow-up. Of note, the rapid regimen triggered a substantial immune response within days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The rapid development and production of a ZIKV vaccine candidate building on a commercial Vero-cell manufacturing platform resulted in a safe and immunogenic vaccine suitable for further clinical development. To optimize antibody persistence, higher doses and a booster administration might be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taac127","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T13:44:15Z","timestamp":1668087855000},"source":"Crossref","is-referenced-by-count":10,"title":["A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine"],"prefix":"10.1093","volume":"31","author":[{"given":"Nina V","family":"Wressnigg","sequence":"first","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Hochreiter","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Schneider","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela J","family":"Obersriebnig","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole I","family":"B\u00e9zay","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lingnau","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena \u010corbi\u0107","family":"Ramljak","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin L","family":"Dubischar","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"2024102415433129600_ref1","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa227","article-title":"Public health emergencies of international concern: a historic overview","volume":"27","author":"Wilder-Smith","year":"2020","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref2","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa165","article-title":"The re-emergence of Zika in Brazil in 2020: a case of Guillain Barre Syndrome during the low season for arboviral infections","volume":"27","author":"Akrami","year":"2020","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref3","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa001","article-title":"Zika outbreak in India in 2018","volume":"27","author":"Biswas","year":"2020","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref4","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz012","article-title":"Zika in Angola and India","volume":"26","author":"Hamer","year":"2019","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref5","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz057","article-title":"Incidence of laboratory-confirmed Zika in Israeli travelers to Thailand: 2016-2019","volume":"26","author":"Leshem","year":"2019","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref6","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa061","article-title":"Zika among international travellers presenting to GeoSentinel sites, 2012-2019: implications for clinical practice","volume":"27","author":"Angelo","year":"2020","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref7","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac002","article-title":"Causes of fever in returning travelers: a European multicenter prospective cohort study","volume":"29","author":"Camprubi-Ferrer","year":"2022","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref8","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa222","article-title":"Dengue, chikungunya and Zika in GeoSentinel surveillance of international travellers: a literature review from 1995 to 2020","volume":"27","author":"Osman","year":"2020","journal-title":"J Travel Med"},{"key":"2024102415433129600_ref9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.03.001","article-title":"Zika virus: History, epidemiology, transmission, and clinical presentation","volume":"308","author":"Song","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2024102415433129600_ref10","volume-title":"Centers for Disease Control and Prevention (CDC): Zika Symptoms","year":"2019"},{"key":"2024102415433129600_ref11","doi-asserted-by":"crossref","first-page":"e0009516","DOI":"10.1371\/journal.pntd.0009516","article-title":"Clinical manifestations and health outcomes associated with Zika virus infections in adults: a systematic review","volume":"15","author":"Halani","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2024102415433129600_ref12","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12616","article-title":"Zika virus and pregnancy: an overview","volume":"77","author":"de Carvalho","year":"2017","journal-title":"Am J Reprod Immunol"},{"key":"2024102415433129600_ref13","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika Virus Infection in Pregnant Women in Rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N Engl J Med"},{"key":"2024102415433129600_ref14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(16)30058-7","article-title":"Guillain-Barre syndrome associated with Zika virus infection","volume":"387","author":"Brasil","year":"2016","journal-title":"Lancet"},{"key":"2024102415433129600_ref15","volume-title":"Zika Virus Research and Development Roadmap, Advanced Draft","author":"WHO","year":"2021"},{"key":"2024102415433129600_ref16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amepre.2019.10.023","article-title":"The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age","volume":"58","author":"Bartsch","year":"2020","journal-title":"Am J Prev Med"},{"key":"2024102415433129600_ref17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2024102415433129600_ref18","volume-title":"U. S. Department of Health and Human Services\/FDA\/CBER: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, Guidance for Industry","year":"2007"},{"key":"2024102415433129600_ref19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"2024102415433129600_ref20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"2024102415433129600_ref21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"2024102415433129600_ref22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"2024102415433129600_ref23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"},{"key":"2024102415433129600_ref24","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO((R))","volume":"29","author":"Schuller","year":"2011","journal-title":"Vaccine"},{"key":"2024102415433129600_ref25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1473-3099(20)30085-2","article-title":"Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial","volume":"20","author":"Stephenson","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024102415433129600_ref26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"2024102415433129600_ref27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(20)30733-7","article-title":"Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102415433129600_ref28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-virology-031413-085453","article-title":"Vaccine development as a means to control dengue virus pathogenesis: do we know enough?","volume":"1","author":"Pierson","year":"2014","journal-title":"Annu Rev Virol"},{"key":"2024102415433129600_ref29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41591-019-0746-2","article-title":"Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor","volume":"26","author":"Dussupt","year":"2020","journal-title":"Nat Med"},{"key":"2024102415433129600_ref30","doi-asserted-by":"crossref","first-page":"107566","DOI":"10.1016\/j.celrep.2020.107566","article-title":"CD4(+) T cells cross-reactive with dengue and Zika viruses protect against Zika virus infection","volume":"31","author":"Wen","year":"2020","journal-title":"Cell Rep"},{"key":"2024102415433129600_ref31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"2024102415433129600_ref32","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11030294","article-title":"Peculiarities of Zika immunity and vaccine development: lessons from dengue and the contribution from controlled human infection model","volume":"11","author":"Santiago","year":"2022","journal-title":"Pathogens"},{"key":"2024102415433129600_ref33","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1038\/s41598-020-60415-6","article-title":"Complete protection in Macaques Conferred by purified inactivated Zika vaccine: defining a correlate of protection","volume":"10","author":"Young","year":"2020","journal-title":"Sci Rep"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taac127\/47560701\/taac127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/7\/taac127\/59887960\/taac127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/31\/7\/taac127\/59887960\/taac127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:43:50Z","timestamp":1729784630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taac127\/6827727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,11,15]]},"published-print":{"date-parts":[[2024,10,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taac127","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2022,11,15]]},"article-number":"taac127"}}